Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PFE$30.02-0.40(-1.31%)Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026[11:18:00 AM ET]BIVI$1.24-0.04(-3.13%)From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television[10:30:00 AM ET]AMGN$439.26-8.02(-1.79%)IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's...[10:30:00 AM ET]JNJ$263.81-3.80(-1.42%)Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of...[8:54:00 AM ET]PBLS$24.79-2.13(-7.91%)Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors[8:45:00 AM ET]SMTC$131.80+6.68(+5.34%)Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026[8:00:00 AM ET]GMAB$43.85+3.85(+9.63%)Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]INCY$115.00-1.93(-1.65%)Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer[7:00:00 AM ET]NBTX$29.36+0.17(+0.58%)NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma[7:00:00 AM ET]ONC$377.63-4.64(-1.21%)BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026[4:15:00 AM ET]CMPX$0.77-0.03(-3.97%)Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026[4:15:00 AM ET]CELC$63.20-2.37(-3.61%)Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026[4:15:00 AM ET]

ACXP · NASDAQ

Acurx Pharmaceuticals, Inc.

$1.10 0.00 (-0.09%)

Company overview

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, which has a novel mechanism of action that targets the polymerase IIIC enzyme and has completed a Phase II clinical trial to treat patients with Clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$6.1M
Employees
4
Headquarters
Staten Island, NY
Website
acurxpharma.com
CEO
David Luci
Listed
June 25, 2021
P/E
-0.22
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$7.6M
EBITDA
-$7.6M
Net income
-$7.5M
EPS
-$4.91
Total assets
$9.5M
Total debt
$0.00
Earnings yield
-446.36%

Price chart

1.021.371.722.082.43
ACXP 1D NASDAQ O1.14H1.14L1.12C1.14-0.00 (-0.09%)Vol2.67K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ACXP Press release From Private Credit to Fusion Power: New to The Street Show #777 Premieres Tonight on Bloomberg Television ACCESS Newswire
ACXP Press release Acurx Announces Publication in ASM Confirming Data on its DNA pol IIIC Inhibitor Pipeline of Antibiotics Demonstrating a Potential Microbiome-Sparing Class Effect Acurx Pharmaceuticals, Inc. PR Newswire
ACXP Press release Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection PR Newswire
ACXP Press release New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global ACCESS Newswire
ACXP Press release Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. PRNewsWire
ACXP Press release Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat PRNewsWire
ACXP Stock news Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call Transcript Seeking Alpha
ACXP Press release Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update PRNewsWire
ACXP Press release FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduc. PRNewsWire
ACXP Stock news Axos Aims to Expand AI-Powered Financial Services With Arc Acquisition PYMNTS
ACXP Press release Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update PRNewsWire
ACXP Stock news Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript Seeking Alpha
ACXP Press release Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update PRNewsWire
ACXP Press release Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026 PRNewsWire
ACXP Press release Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase PRNewsWire
ACXP Press release Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit Newsfile Corp
ACXP Press release Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update PRNewsWire
ACXP Press release Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PRNewsWire
ACXP Press release Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules PRNewsWire
ACXP Stock news Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research
See more
FAQ

Questions about Acurx Pharmaceuticals, Inc.

What does Acurx Pharmaceuticals, Inc. do?
Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, which has a novel mechanism of action that targets the polymerase IIIC enzyme and has completed a Phase II clinical trial to treat patients with Clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
What is ACXP's market cap?
Acurx Pharmaceuticals, Inc. (ACXP) is a listed stock with a live quote. The latest market cap on this page is $6.1M.
Where is Acurx Pharmaceuticals, Inc. headquartered?
Acurx Pharmaceuticals, Inc. is headquartered in Staten Island, NY.
How do I get ACXP news from the API?
Call GET /v1/news?tickers=ACXP. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does ACXP news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ACXP, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the ACXP price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 2,000 REST requests a day. Paid Pro removes the daily cap. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs